Detailed Notes on M3541
MI-CP151 was a period 1b randomised, double-blind, placebo managed, dose-escalation, multicentre analyze To guage many intravenous doses of sifalimumab, in Grownup patients with dermatomyositis or polymyositis (NCT00533091). Major demo targets were to evaluate the security and tolerability of sifalimumab in dermatomyositis or polymyositis patients,